Neurotrauma frequently results in neuropathic pain. Our earlier studies revealed that peripheral neurotrauma-induced fragmentation of the myelin basic protein (MBP), a major component of the myelin sheath formed by Schwann cells, initiates a pain response from light touch stimuli (mechanical allodynia) in rodents. Here, we identified the cyclin-dependent kinase 5 (CDK5), as an intracellular interactor of MBP in Schwann cells. The algesic peptide fragment of MBP directly associated with CDK5. When complexed with its p25 coactivator, CDK5 phosphorylated the conserved MBP sequence. The expressed MBP fragment colocalized with CDK5 in Schwann cell protrusions. Roscovitine, an ATP-competitive CDK5 inhibitor, disrupted localization of the expressed MBP peptide. Mutations in the evolutionary conserved MBP algesic sequence resulted in the interference with intracellular trafficking of the MBP fragment and kinase activity of CDK5 and diminished pain-like behavior in rodents. Our findings show that MBP fragment amino acid sequence conservation determines its interactions, trafficking, and pronociceptive activity. Because CDK5 activity controls both neurogenesis and nociception, the algesic MBP fragment may be involved in the regulation of the CDK5 functionality in pain signaling and postinjury neurogenesis in vertebrates.
Introduction
Mechanosensitive axons of the peripheral nervous system (PNS) are insulated by the myelin sheath, a multilamellar membrane that permits propagation of action potential from mechanical stimulation [1] . Schwann cells form the myelin sheath by enwrapping their cell membranes around mechanosensitive afferent axons [2] . Demyelination in PNS injury is thought to contribute to severe neuropathic pain states, including pain from light touch, or
We previously reported that physical injury in the PNS microenvironment stimulates the proteasemediated cleavage of MBP and the release of fragments comprising the invariant a-helix motif. These fragments accumulate at the paranodal/nodal regions of the damaged myelinated fibers. A single injection of synthetic peptides comprising this MBP sequence into an intact nerve is sufficient to produce robust mechanical allodynia sustained for weeks in rodents [3, [6] [7] [8] . However, the molecular identity of cellular proteins that interact with the algesic MBP peptides was unknown. Here, we investigated the cellular interactions and the role of the amino acid sequence conservation in its relationship with the cell components that are involved in the peptide trafficking mechanisms in Schwann cells.
The present study provides the experimental evidence that the algesic MBP peptides directly bind CDK5. CDK5 is an intracellular serine/threonine kinase and a global orchestrator of neuronal cytoskeletal dynamics, including sensory PNS neurons [9] . CDK5 deregulation contributes to neurodegeneration [10] [11] [12] [13] [14] [15] and pain signaling [16, 17] . CDK5 phosphorylates a diverse list of substrates, including TRPV1 and NMDA receptors, implicating its activity in a broad range of cellular processes during pain states [16] [17] [18] . CDK5 is bound to the cell membrane via its interactions with the p39 and p35 noncyclin activator proteins [19, 20] . Cleavage of the p39 and p35 by calpain results in the N-end truncated p29 and p25 activators. As a result, the stable CDK5 complex with either p29 or p25 and with the elevated activity is trafficked from the membrane to the cytoplasm and the nucleus. Our findings established that the reciprocal interaction between CDK5 and the algesic MBP peptides represents a novel molecular mechanism of intracellular MBP trafficking and depends on the MBP sequence conservation. The sequence conservation of the algesic MBP peptide is essential in the development of neuropathic pain.
Results

Synthetic MBP epitope internalizes and localizes to cell projections in cultured Schwann cells
The algesic MBP84-104 cryptic epitope is released in the nerve postinjury as a result of proteolysis of MBP. In our earlier studies, the injection of the main algesic, autoimmune MBP84-104 epitope that is hidden in the native MBP fold, into an intact nerve was sufficient to induce robust, long-lasting allodynia in rodents [3, [6] [7] [8] . Peptides representing MBP epitope region MBP80-99 and MBP84-104 exhibit a high level of amino acid conservation among evolutionary distant animal species (Fig. 1A , Table 1 ). Notably, the highly conserved motif 87-VVHFF-91 representing an alpha-helix [21] was present in both peptide species. The MBP epitope region is encoded by exons 3-4 of all four classic MBP splicing variant, and exons 6-7 of variant 1 of the Golli MBP in humans (Fig. 1B) .
We initially screened whether the synthetic MBP peptides can specifically bind receptors on the surface of Schwann cells, the dominant cell type and thus, the likely source for MBP interactors in MBP-injected nerves [8] . The synthetic fluorescently labeled MBP peptide MBP80-99 was administered extracellularly to the primary rat Schwann cell cultures. After 30 min incubation, cells were fixed and fluorescent signals were recorded using in situ epifluorescent microscopy. Using a FITC-labeled MBP80-99-FITC peptide, we detected its specific association with the cell periphery, including in cell projections/lamellipodia ( Fig. 2A ). This specific association was not observed with the scramble MBP80-99-SCR-FITC-labeled peptide.
The competitive titration of MBP80-99-FITC using a fourfold excess of unlabeled MBP80-99 peptide reduced the signal intensity thus supporting the specific nature of cell projection binding of MBP80-99-FITC (Fig. 2B ). The signal specificity was further confirmed by coincubation of FITC-and Tetramethylrhodamine (TMR) labeled MBP80-99 peptides. The FITC-and TMR-specific signals juxtaposed at cell periphery loci (Fig. 2C) .
Trafficking of the algesic MBP peptide to Schwann cell lamellipodia relies on MBP amino acid sequence conservation
To identify the potential cellular interactors of the internalized algesic MBP peptide, we designed a specialized expression construct that encoded the three head-to-tail-linked MBP68-102 sequences C-terminally tagged with mCherry (MBP-WT-mCherry, Fig. 2D , Table 2 ). Based on the well-established knowledge by others, we used the MBP-tripeptide-mCherry constructs, rather than a monopeptide construct, to achieve a better protein stability and to signal readout, as well as to directly monitor the tagged construct in the cell milieu. We have also designed the mutant construct that deviated from the highly conserved in vertebrates central alpha-helix 84-95 portion of MBP (residues are numbered according to human MBP, GenBank NP_001020261). In the mutant construct, amphoteric Gly-89 substituted for the basic His-89 (MBP-H89G-mCherry).
Both constructs were expressed in rat Schwann cells and the subcellular localization of the constructs was then recorded. The MBP-WT-mCherry construct was consistently trafficked to the Schwann cell lamellipodial protrusions involved in myelination (Fig. 2D) . In contrast, the lamellipodia-specific signals could not be observed in cells expressing the H89G mutant. We concluded that the cell protrusion-directed trafficking of the algesic MBP fragment occurs via amino acid sequence-specific binding to a cellular interactor molecule(s).
Expression of MBP peptide activates pain-related signaling pathways
To determine which signaling pathways became altered in response to the MBP-WT-mCherry expression in Schwann cells the genome-wide transcriptome analysis was conducted. Naive Schwann cells were used as a control. RNA sequencing (RNA-seq) was performed using NextSeq 500 DNA sequencer (Illumina, San Diego, CA, USA), RNA-seq read data were mapped to the Rattus norvegicus genome (version Rn5) and normalized using CUFFLINKS software (http://cole-tra pnell-lab.github.io/cufflinks/). To predict the effect of MBP-WT-mCherry on the regulation of canonical signaling pathways the gene expression data (log 2 (FPKM) ≥ 0.01) were analyzed using IPA (Qiagen, Valencia, CA, USA) (Fig. 3) . We compared the activated canonical pathways in Schwann cells to our previously published gene expression data [7, 8] . The latter were obtained after the intrasciatic injection of the MBP84-104-WT peptide in female rats (n = 6). In MBP84-104-WT  ENPVVHFFKNIVTPRTPPPSQ  MBP84-104-H89G  ENPVVGFFKNIVTPRTPPPSQ  MBP84-104-SCR  SHVPFNTEQPFPVNVPKPRIT  MBP84-104-pT96  ENPVVHFFKNIVpTPRTPPPSQ  MBP84-104-pT99  ENPVVHFFKNIVTPRpTPPPSQ  MBP84-104-T96A/T99A  ENPVVHFFKNIVAPRAPPPSQ  MBP80-99-FITC/TMR RTQDENPVVHFFKNIVTPRT 7 days after the intrasciatic peptide injection the specimens of sciatic nerves, dorsal root ganglia, and dorsal spinal cord were collected and the coding RNAs were analyzed by the genome-wide transcriptional profiling using microarray (GEO dataset GSE34868).
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Our comparative system biology analysis (Fig. 3 ) indicated that at least 38 signaling pathways activated in both Schwann cells expressing MBP84-104-WTmCherry and rat nerves injected with the peptide. These pathways included VEGF signaling, neuroinflammation signaling, paxillin signaling, IL-6, IL-8, and IL-2 signaling, p38/MAPK, CDK5 signaling, purinergic receptor signaling, and others. These data suggest that Schwann cells expressing MBP-WTmCherry exhibit the characteristics that are comparable to our MBP-mediated pain models in rodents.
The MBP peptide specifically interacts with CDK5
We used a mCherry antibody to pull-down the MBP-WT-mCherry and MBP-H89G-mCherry constructs and the associated proteins from the lysates of the respective transfected Schwann cells. Intact Schwann cells were used as a control. To determine the identity of the copulled-down proteins, the precipitated material was subjected to the LC-MS analysis using a linear trap quadrupole mass-spectrometer (LTQ-MS). Seventeen unique proteins were present in the pulled-down MBP-WT-mCherry samples relative to the control (Table 3) , including CDK5, actin-related protein 2/3 complex subunit 1A (ARPC1A) [22] , plakoglobin (JUP) [23] , and testin (TES) that are known to be associated with cell junctions, focal adhesions, and cell protrusions -lamellipodia.
We evaluated the copulled-down samples by immunoblotting using the CDK5, ARPC1A, JUP, and TES antibodies. The samples were positive for the presence of CDK5 (Fig. 4A) , while other four proteins were undetectable (data not shown). Next, we pulleddown the MBP-H89G-mCherry construct and compared side-by-side the level of CDK5 in the WT and H89G-precipitated samples. Our results indicated that the H89G mutant exhibited the reduced ability to bind to CDK5 (Fig. 4A ).
CDK5 and MBP colocalize in Schwann cells
We coexpressed MBP-WT-mCherry and the human CDK5 fused to a ZsGreen1 tag (CDK5-ZsGreen1) in cultured Schwann cells. A significant level of colocalization of both constructs was detected in cell projections (Fig. 4B ,C, Movie S1). In addition, we observed a significant localization of MBP-WT-mCherry to cell nuclei. The expressed MBP-WT-mCherry alone did not result in accumulation of fluorescent signals in cell nuclei. Because CDK5 protein is known to localize in both cell periphery and nuclear/perinuclear regions [24, 25] we proposed that the exogenously overexpressed CDK5 is responsible for nuclear trafficking of MBP-WT-mCherry. We incubated Schwann cells expressing CDK5-ZsGreen1 with extracellularly administered TMR-labeled MBP80-99 peptide. Using confocal imaging we observed colocalization of CDK5 and MBP80-99-TMR-specific signals in both cell . Naive Schwann cells were used as a control (SC). Whole transcriptome sequencing was conducted using NextSeq 500 instrument (Illumina). RNA-seq read data were mapped to R. norvegicus genome (version Rn5) and normalized using CUFFLINKS software. RNA-seq data (Log 2 (FPKM) ≥ 0.01) were analyzed using Ingenuity IPA knowledgebase (Qiagen, version 2017) to predict the regulation of signaling pathways. RNA-seq data were compared to gene expression data from our previously published study [7, 8] in which MBP84-104 peptide was intrasciatically injected in female rats and the following 7 days specimens of ipsilateral sciatic nerves (SN/MBP), dorsal root ganglia (DRG/MBP), and dorsal spinal cord (DSC/MBP) were collected, pooled (n = 6 per animal group), and total RNAs were profiled using gene expression microarrays (GEO ID GSE34868). Color scales represent predictive activation (red) or inactivation (blue) of signaling pathways based on their z-scores.
protrusions and cell nuclei ( Fig. 4D ) consistent with the coexpression data ( Fig. 4B ,C). We concluded that the extracellular MBP peptide can be internalized by Schwann cells and CDK5 binds both extracellularly administered and the expressed MBP peptide species.
CDK5 phosphorylates the algesic MBP peptides
The algesic MBP sequence comprises multiple potential phosphorylation sites sharing a consensus motif Thr/Ser-Pro [26, 27] . The kinase substrate prediction suggested that Thr-96 and Thr-99 can be targeted by multiple Thr/Ser-specific protein kinases, including mitogen-activated protein (MAP) kinases and CDKs ( Fig. 5A ) [26] . CDK5 was predicted to phosphorylate the Thr-96, Thr-99, and Ser-166 (Fig. 5B ). Using LTQ-MS of proteins in the MBP-WT-mCherry pulldown sample, we detected the NIVpTPRTPPPA-HYGSLPQK fragment with phosphorylated Thr-96 (data not shown). Based on these data, we hypothesized that CDK5 binds to the MBP peptides and then phosphorylates either Thr-96 or Thr-99, or both.
To test if the cryptic algesic peptides are CDK5 substrates, the MBP84-104-WT, MBP84-104-H89G, and MBP84-104-SCR synthetic peptides were coincubated with the purified CDK5/p25 and the level of phosphorylation was then measured by the incorporation of c-
33
P. We also used the MBP84-104-WT peptides with synthetic phospho-threonine (pT) at either 96 or 99 positions to determine which individual Thr residue is phosphorylated. The MBP84-104-WT peptide but not the scrambled peptide was efficiently phosphorylated by CDK5/p25 (Fig. 5C ). The H89G mutation reduced the level of the peptide phosphorylation at least twofold suggesting that the amino acid conservation of the invariant motif 87-VVHFF-91 is important for the CDK5 interactions with the algesic MBP. The level of CDK5-dependent phosphorylation of the MBP84-104-WT peptides with either pT96 or pT99, was reduced more than twofold relative to the unmodified peptide. These data implied that both Thr-96 and Thr-99 in the algesic peptide were phosphorylated by CDK5 with a roughly similar efficacy.
Roscovitine disrupts the MBP peptide-CDK5 interactions
Roscovitine is a broad-range purine inhibitor of CDKs, including CDK5, through its direct competition at their ATP-binding site [28, 29] . Based on our modeling data, we hypothesized that roscovitine would interfere with the CDK5-MBP peptide interactions. To test this model, we coincubated roscovitine for 2 h with Schwann cells coexpressing the MBP-WT-mCherry and CDK5-ZsGreen1 constructs. In the absence of roscovitine, the CDK5 and the MBP peptide immunoreactivity overlapped, especially in the nucleus and cell protrusions (Fig. 6A ). In the presence of roscovitine, the MBP peptide immunoreactivity was detected in the cell protrusions, but not in the nucleus. In turn, cell protrusions became free of CDK5 fluorescence which persisted in the nucleus. These findings implied that roscovitine effectively blocked the MBP peptide-CDK5 complex and liberated MBP peptide-free CDK5 from Schwann cell protrusions, yet had no effect on CDK5 translocation to the nucleus.
ATP hydrolysis by CDK5 is affected by His-89
Similar to others [30] , we measured ATP to ADP conversion catalyzed by CDK5/p25 in the presence of MBP84-104-WT, MBP84-104-H89G, MBP84-104-SCR, and MBP84-104-WT with either synthetic pT96 or pT99. Except MBP84-104-H89G, the effect of the peptides on CDK5 activity was insignificant. In contrast, the mutant peptide considerably reduced the ATP to ADP conversion suggesting the vital importance of the conserved 87-VVHFF-91 motif in the physiological regulation of the CDK5 function (Fig. 6B) . We hypothesized that the conserved 87-VVHFF-91 motif of the CDK5-bound algesic MBP84-104 wildtype peptide is positioned near the ATP-binding site.
Mutations in its conserved sequence led to the interference with the ATP to ADP conversion. To model the CDK5 complex with the ENPVVHFFKNIV pTPRTPPPSQ peptide, we used the structures of CDK5/p25 (PDB: 3o0g) [31] and the MBP fragment bound to HLA-DR2 (PDB: 1vf1) [32] . The fold of the pT96 region in the CDK5 active site was modeled based of the positions of the substrate peptides in the active site of CDK2 [33, 34] . The CDK2 structure was aligned with CDK5 (PDB: 3o0g) and then the positions of the main chain of the MBP peptide were aligned with the CDK2 substrate peptides. This approach allowed us to define the relative positions of the P3 and P4 residues (K and N in the MBP peptide, respectively) and roughly assess the general fold of the peptide bound to the CDK5 globule (Fig. 6C) . Accordingly, the peptide chain including P7 His-89 is localized near the negatively charged ATP-binding site of CDK5. Alterations of the MBP peptide sequence may alter the peptide fold that potentially interferes with ATP binding in the CDK5 ATP-binding pocket and consequently inhibit the ATP to ADP conversion. 
His-89 alters the algesic potency of the MBP peptide
To determine if the His-89 mutation affected not only the trafficking pathway of the MBP84-104 peptide but also its algesic potency, the three synthetic peptidesthe wild-type (MBP84-104-WT), the H89G mutant (MBP84-104-H89G), the scrambled peptide (MBP84-104-SCR), and T96A/T99A dual mutant (MBP84-104-T96A/T99A) -were each administered by intrafascicular injection into sciatic nerve in rats (Fig. 7A) . The animals were then subjected to von Frey testing for 7 days. The withdrawal thresholds in von Frey tests in the ipsilateral paw of rats that received the MBP84-104-WT peptide dropped within day 1 postinjection, indicative of the robust mechanical allodynia (Fig. 7B) . Withdrawal thresholds remained low in animals injected with MBP84-104-WT peptide for the entire 7-day test period, especially when compared with the scrambled peptide that was inactive in our von Frey tests (P ≤ 0.05). Notably, the pain-inducing efficacy of a MBP84-104-T96A-T99A dual mutant peptide was reduced on days 2-7 as compared to the wild-type peptides. A single H89G mutation was sufficient to significantly reduce the pain-inducing efficacy of the peptide. Apart from the mechanical paw hypersensitivity behavior, the rats demonstrated no additional behavioral alterations, consistent with our previous data [7, 8] .
To corroborate the von Frey findings, we determined the expression levels of the interleukin 6 (IL-6, or interferon b2) [35] and activating transcription factor 3 (ATF3) [36] in the respective lumbar 5 dorsal root ganglia (L5 DRG) containing the sensory neuronal cell bodies [7] . At day 9 postinjection both Il6 and Atf3 genes were induced following the injection of MBP84-104-WT but not the scramble or H89G peptides (Fig. 7C ). In agreement with our von Frey tests, an increase of intraganglionic IL-6 and ATF3 was observed only in the MBP84-104-WT samples (Fig. 7D ), but not in the H89G mutant and scramble peptide samples (data not shown).
Localization of MBP peptides in PNS
In the PNS, Schwann cells myelinate the nerves and synthesize MBP. Schwann cells are the main immunoreactive cell type for the algesic MBP peptide postinjury and the main cell type in the MBP-injected nerve [6, 8] . Furthermore, the MBP68-102 peptide translocates toward the paranode/node of Ranvier (NoR) of the Schwann cell-axon unit, as shown in fibers teased out from the nerve at day 1 postaxotomy (Fig. 8A ), in agreement with our previous report [6] . Our comparative transcriptional profiling determined elevated expression of the CDK family genes, including CDK5, in nerve microenvironment at day 1 postaxotomy (Fig. 8B and GEO dataset GSE34868) corroborating the earlier reports of CDK5 expression in the PNS [9, 37] . Myelinating Schwann cells of characteristic crescent morphology produce both the MBP68-102 peptide and CDK5 in nerve at day 1 postaxotomy (Fig. 8C) . Based on our in vitro and in vivo data, we propose a model of CDK5-dependent translocation of the algesic MBP to the Schwann cell lamelopodia toward the paranodes and nodes of Ranvier (Fig. 8D) , the sites of pain-related ion channel clustering [38] .
Together, our data for the first time demonstrate the direct interactions between CDK5 and the highly conserved, pronociceptive and autoantigenic MBP84-104 sequence. Our results suggest that the algesic function of the degraded MBP peptide species in PNS is CDK5-dependent. The reciprocal nature of this relationship is evidenced from the ability of the kinase to phosphorylate MBP84-104, as the amino acid sequence conservation is required to sustain ATP hydrolysis regulated by CDK5.
Discussion
Normally, pain serves as an alarm of impending danger. But an injury in the PNS leading to a damage of the myelin sheath may contribute to a chronic state of neuropathic pain termed mechanical allodynia [1, 3] . MBP is a component of the myelin sheath synthesized by Schwann cells. After nerve injury, the upregulated protease activity cleaves MBP [3, 6, 8] . While the released proteolytic fragments activate the pronociceptive machinery, the underlying molecular mechanisms remained elusive. We previously reported that intrasciatic injections of the synthetic peptides corresponding to the 68-102 sequence of MBP that is hidden in the native intact MBP fold reproduce long-lasting mechanical allodynia [3, [6] [7] [8] . This MBP region folds into amphipathic a-helix and exhibits remarkable conservation in vertebrates (Fig. 1A) . The corresponding MBP fragments are known primary immunodominant epitopes in multiple sclerosis [39] . The 89-HFFK-92 pocket is essential to T cell receptor recognition [5] . peptides prior to T cell recruitment to the nerve and the development of the MBP-induced pain is only partially depended on T cells as shown using T cell-deficient nude rats [8] . Phosphorylation of full-length MBP by CDK5 and other protein kinases has been reported previously [40] [41] [42] .Threonine residues Thr-96 and Thr-99 can be phosphorylated by kinases including ERK1 and ERK2 [43] . Furthermore, other residues, such as His-89 and Lys-92, also may undergo phosphorylation to yield difficult to detect acid-labile phosphoramidates [44] [45] [46] .
Here, we report that the wild-type peptides derived from the algesic MBP sequence directly interact with CDK5 in Schwann cells. CDK5 is a unique CDK family enzyme known to orchestrate cytoskeletal dynamics in the nervous system and a well-established component in pain signaling processes [16, 17, 47] . CDK5 phosphorylates and regulates the activity of a number of major substrates central to nociception, including N-methyl-D-aspartate (NMDA) [48] , P/Q-type voltage-dependent calcium channel (VDCC) [49] , transient receptor potential vanilloid receptor-1 (TRPV1) [50] , potassium voltage-gated channel Kv2.1 [51] , and ATP-gated ion channels [52, 53] . Aberrant phosphorylation by CDK5/p25 is involved in pathological neurodegenerative states including Alzheimer's disease, brain injuries, Parkinson's disease, and ALS [11] [12] [13] [14] [15] . We demonstrated that CDK5 bound to the algesic MBP sequence and then phosphorylated both Thr residues. The MBP binding to CDK5 greatly affected both its cell compartmentalization and enzymatic activity. However, whether this molecular event affects the functions of MBP or CDK5 in pain versus in normal development warrants future investigation. The selective trafficking to the Schwann cell protrusions and algesic activity were repressed in the mutant MBP peptides, highlighting the importance of the amino acid sequence conservation of the MBP hidden epitope. Schwann cells release signals that guide the assembly of multiprotein cell adhesion, ion channels, and scaffolding complexes into the distinct longitudinal myelin domains [38] . MBP has a well-established role in myelin compaction by regulation of the multiprotein and lipid cell adhesions of the opposing Schwann cell membranes [4] . Our experimental results also support and extend the earlier observations by others [54] who identified the phosphorylation-dependent active nuclear trafficking of MBP.
Inherently, myelinating Schwann cells are the source of myelin proteins in the PNS, including MBP [2] . Physical disruption of the Schwann cell-axon unit and its plasma and myelin membranes caused by nerve injury releases myelin peptides. The algesic MBP84-104 peptide is primarily localized in Schwann cells in vivo [6, 8] consistent with its efficient internalization in cultured Schwann cells. The endogenous MBP peptide does not colocalize with macrophages in the postinjury nerve [6] implying that the peptide escapes the macrophage-mediated phagocytosis. Inhibition of matrix metalloproteinases both blocks the MBP epitope release and diminishes pain caused by nerve injury [3, 6, 8] .
The myelin lamellae terminate at the Schwann cell cytoplasm-filled paranodal loops in a close proximity to action potential propagation, ionic fluxes, and extensive phosphorylation/dephosphorylation of the molecular machinery at the paranode and NoR, the sites of pain-related ion channel clustering [2, 38] . The algesic MBP fragments are selectively internalized by mechanosensory A-fibers (inherently myelinated) and not nociceptive C-fibers (inherently unmyelinated), producing pain from mechanical but not thermal stimulation [6] [7] [8] . Both MMPs and the algesic MBP peptides translocate toward the paranode/NoR regions in response to nerve injury [8, 55] . The algesic MBP peptides accumulation in the Schwann cell protrusions in vitro and the paranodal/nodal regions following nerve trauma is likely to be central to their algesic action [8, 56] .
In the nodal/paranodal area, the site of the CDK5-MBP binding, the energy demand is high. To support extensive ionic fluxes and action potential propagation, the energy is commonly released in the form of ATP. Our data indicate that CDK5 promotes hydrolysis of ATP more efficiently using the H89G mutant peptide as substrate compared to the wild-type peptide. Our modeling suggests that the H89G mutant fold may interfere with the ATP binding. In turn, the original peptide does not interfere with the ATP binding and, as a result, is efficiently phosphorylated. These data imply that conservation of this sequence region of MBP is important. Conversely, if this conservation is abolished, the mutant MBP sequence may interfere with the ATP binding to CDK5 and CDK5 function in general.
Our data suggest that the binding mode of the algesic MBP fragments involves regions proximal to the ATPbinding site of CDK5. Given the two-substrate kinetics, it is plausible that the algesic MBP peptide binding to CDK5 would affect the efficiency of ATP conversion to ADP. ATP alters nociceptive sensitivity via the ATPgated P2X receptor cation channels localized at the site of nerve injury [57] . Our results also imply that mutations that potentially destroy the invariant helical structure of the 68-102 MBP region may lead to the fold that affects both the kinase activity of CDK5 and the algesic ability of MBP. Conservation of this MBP region in vertebrates may protect the vital CDK5 functionality in neurogenesis or nociception. In sum, our study identified CDK5 as an intracellular target of the specific immunodominant, algesic fragments of MBP. Whether or not this interaction contributes to pain facilitation warrants investigation, but it clearly controls cellular trafficking of the algesic MBP fragments. Sequence conservation of the algesic 68-102 MBP peptides in vertebrates defines the molecular mechanism in its functional regulation of neuropathic pain.
Materials and methods
Reagents and antibodies
Reagents were purchased from Thermo Fisher Scientific . Roscovitine (Cayman Chemical, Ann Arbor, MI, USA) was dissolved (10 mM) in DMSO and diluted to 10 lM in culture medium prior to use [29] or delivered at 25 mgÁkg À1 in DMSO [58] in vivo.
Peptides (Table 1) were synthesized by GenScript (Piscataway, NJ, USA) and purified using HPLC. DNA oligonucleotides and synthetic DNA were generated by Integrated DNA Technologies (San Jose, CA, USA).
Cloning of expression constructs
Synthetic cDNA encoding three MBP68-102 fragments (Table 2 ) and synthetic DNA encoding the mCherry tag [59] were joined and cloned into the linearized pCpGfreevitroBmcs vector (Invivogen, San Diego, CA, USA) using isothermal assembly (New England Biolabs, Ipswich, MA, USA). The wild-type and H89G mutant pAC-MBP-WTmCherry and pAC-MBP-H89G-mCherry expression plasmids, respectively, were next constructed and their identity was validated by DNA sequencing. The signal peptide (MKTIIALSYIFCLVFAD) of the influenza hemagglutinin (hsp) [60] was added to the N-terminus of both the wild-type and mutant sequences by DNA synthesis producing pAChsp-MBP-WT-mCherry and pAC-hsp-MBP-H89G-mCherry expression constructs, respectively. CDK5 cDNA (GenBank NM_004935.2) was amplified using primers CDK5-GA-F (TAC AGT AGC TTC CAA GTC ACC ATG CAG AAA TAC GAG AAA CTG GAA) and CDK5-GA-R (GTG CAC TAG ATC TTA GTA CTC CGG GCG GAC AGA AGT CGG AGA). CDK5 and a synthetic DNA fragment encoding the C-terminal ZsGreen1 (fluorescent protein derived from Zoanthus sp. reef coral [61] ) were assembled and cloned into the linearized pCpGfree-vitro Bmcs vector using isothermal assembly. All constructs were validated by DNA sequencing.
Cell culture
Primary Schwann cells were isolated from sciatic nerves of postnatal (day 1-3) Sprague-Dawley rats [62] . Cells were purified from fibroblasts using 10 lM cytosine arabinoside (AraC), an anti-fibronectin Thy1.1 antibody, and the rabbit complement [63] . Schwann cell purity was confirmed by S100B staining [62] . 
Transfection of Schwann cells
Cells were grown to 80-90% confluency before transfection. Cells (1 9 10 6 ) were transfected using the recombinant DNA (1 lg) and Lipofectamin 3000. Cells were analyzed after 48 h post-transfection. Positive cells were enriched by passaging in the medium containing 10 lgÁmL À1 blasticidin S (Invivogen).
RNA-seq and system biology analysis
Total RNA was extracted from Schwann cells using TRI reagent (Zymo Research, Irvine, CA, USA) and purified using Direct-zol microRNA system (Zymo Research). The RNA purity was estimated by measuring the OD260/280 ratio using a ND-1000 spectrophotometer (ThermoFisher Scientific). RNA integrity was determined using 2100 Bioanalyser (Agilent Technologies, San Diego, CA, USA). Poly(A) RNA was enriched using the NEBNext Poly(A) mRNA Magnetic Isolation Module (New England Biolabs). Ribosomal RNA was depleted using NEBNext rRNA Depletion reagents (New England Biolabs). A NEBNext Ultra Directional II RNA Library Preparation Kit for Illumina (New England Biolabs) was used to obtain barcoded cDNA libraries from total RNA. Barcoded libraries were pooled and the High Output v2 kit (IlluminaO) was employed to prepare the sequencing libraries.
Libraries were sequenced on a NextSeq 500 DNA sequencer (Illumina). The reads data were processed using BASESPACE software (Illumina). Reads were aligned to R. norvegicus genome (version Rn5) using STAR aligner [64] with default settings. Statistical data processing and differential transcript expression was determined using the Cufflinks package (http:// cole-trapnell-lab.github.io/cufflinks/). Global differential expression analysis was conducted using the previously published workflow [65] . Biological pathway analysis and comparison were performed using Ingenuity Pathway Analysis (Qiagen). RNA-seq datasets were deposited in the GEO database (GSE107020).
Immunoprecipitation
Cells (5 9 10 6 ) were grown in a 100 mm dish to reach a 
Immunocytochemistry
Cells were seeded in wells of poly-D-lysine-coated 96-well glass-bottom Sensoplate (Greiner Bio-One, Monroe, NC, USA) and grown to 70% confluency. Cells were fixed for 10 min in 2% formaldehyde/PBS (Tousimis, Baltimore, MD, USA) at 25°C, permeabilized in 0.1% Triton X-100/ PBS, and blocked in 4% BSA in PBS. Cells were incubated for 1 h with the respective primary antibodies followed by incubation (30 min; 25°C) with species-specific secondary antibody. Cells were mounted on slides using the Prolong Gold reagent (Life Technologies) containing 4 0 ,6-diamidino-2-phenylindole (DAPI). Confocal microscopy was conducted using a LSM 710 NLO Zeiss Multiphoton Laser Point scanning confocal microscope equipped with a multiphoton Mai-Tai laser HB -DeepSee system (690-1024 nm). Images were acquired using ZEN software (Zeiss, San Diego, CA, USA). Alternatively, a Spinning Disc confocal microscope DSU-IX81 (Olympus, Boston, MA, USA) was used and images were captured using SLIDEBOOK software (Olympus). Images were further processed using IM-AGEJ (http://www.macbiophotonics.ca) and combined in Photoshop CC (Adobe System, San Jose, CA, USA). Signal colocalization was determined using Coloc2 utility (http://imagej.net/coloc_2).
Protein phosphorylation assays
Reactions were performed at ambient temperature in 25-lL reactions consisting of 10 nM of the kinase/activator complex (Kinexus, Vancouver, BC, Canada) and 500 lM peptide subtrates in the kinase assay buffer (Kinexus). The reactions were initiated by the addition of 1.25 nmol of [c- 
ATP hydrolysis assay
Reactions (50 lL each) were performed at ambient temperature using Universal Fluorimetric Kinases Assay system (Sigma-Aldrich). Each reaction consisted the CDK5/p25 complex (10 nM each; Sigma-Aldrich) and the substrate peptides (25-100 lM each). The reactions were initiated by the addition of 50 lM ATP. ADP accumulation was recorded in using a microplate reader. Enzyme kinetics data were processed using GRAPHPAD PRISM (GraphPad Software, La Jolla, CA, USA).
Animal models
Female Sprague-Dawley rats (8-10 weeks old, 200-225 g) were obtained from Envigo Labs and housed in a temperature-controlled room ( $ 22°C), on a 12-h light/dark cycle with free access to food and water. The procedure and testing were conducted during the light cycle. Under isoflurane anesthesia, the common sciatic nerve was exposed unilaterally at the midthigh level. A single intrasciatic bolus injection of the MBP peptides (60 lg in 5 lL PBS each) was performed into a nerve fascicle using a 33-gauge needle on a Hamilton syringe. In a separate animal cohort, nerves were transected using surgical scissors to produce axotomy. Sciatic nerve segments (injection site; the proximal and distal to axotomy) and L5 DRG were collected for the quantitative RT-PCR and immunostaining analyses. Tissues from na€ ıve animals were used as a control. Animals were sacrificed using Beuthanasia IP (Schering-Plough Animal Health). All animal procedures were performed in agreement with the PHS Policy on Humane Care and Use of Laboratory Animals and the protocol approved by the Institutional Animal Care and Use Committee at the VA San Diego Healthcare System.
von Frey test
Sensitivity to non-noxious mechanical stimuli was measured using the up-and-down method [66] by an investigator unaware of the animal groups. The plantar surface of the hind paw was stimulated using calibrated von Frey filaments (Stoelting, Wood Dale, IL, USA). Baseline measurements were done for three consecutive days before and then up to daily after the MBP peptide injection. Stimuli were applied for 2 s with a 0.4-15.0 g buckling force to the midpaw plantar surface with ascending filament stiffness until a paw withdrawal response occurred. Stimuli were separated by several-second intervals or until the animal was calm with both hind paws placed on the grid. The consecutive way of applying filaments was continued until six responses were recorded. The 50% threshold was calculated as described [66] .
Nerve immunostaining
In cryoprotected, OCT-embedded, 4% paraformaldehydefixed 10-lm thick DRG sections, nonspecific binding was blocked using 5% donkey serum in 0.3% Triton X-100 for 30 min at ambient temperature. Teased nerve fibers were prepared from desheathed sciatic nerves at day 1 postaxotomy, distal segments. Nerve bundles were separated using forceps, incubated for 1 h in PBS substituted with 5% fish skin gelatin and 0.1% Triton X-100 (PBS/Gelatin/Triton). Individual fibers were teased out using 0.20-to 0.22-mm acupuncture needles (Vinco, Oxford Medical Supplies, Kingham, UK) and dried. The slides were incubated with a primary antibody (16-18 h at 4°C) followed by the species-specific Alexa 488-conjugated secondary antibody (green; 1 h, ambient temperature), a second primary antibody (16-18 h, 4°C) , and the species-specific Alexa 594-conjugated secondary antibody (red; 1 h, ambient temperature). The slides were rinsed in PBS and mounted using the Slowfade Gold antifade reagent containing DAPI. Signal specificity was confirmed by omitting the primary antibody. The images were acquired using a LEICA DMRB MICROSCOPE and OPENLAB software (PerkinElmer).
RT-PCR
Total RNA was extracted from DRG using TRIzol (Invitrogen) and purified on an RNeasy mini column (Qiagen). The RNA purity was estimated by measuring the OD260/ 280 ratio. The samples were treated with RNase-free DNAse I (Qiagen). cDNA was synthesized using a SuperScript first-strand RT-PCR kit (Invitrogen). Real-time RT-PCR was conducted using MX3005P qPCR System (Agilent) in 25-lL reactions containing Taqman Universal PCR Master Mix (Ambion), cDNA (50 ng), specific forward and reverse primers (900 nM each), and Taqman probes (200-300 nM) for Il-6 and Atf3 mRNAs [7] with a one-step program: 95°C, 10 min; 95°C, 30 s; 60°C, 1 min for 50 cycles. Duplicate samples without cDNA (a no template control) showed no contaminating DNA. Normalization to GAPDH and relative mRNA quantification were calibrated to na€ ıve samples using the 2 (-Delta Delta C(T)) method [67] . The fold-change calculations were performed using MXPRO QPCR software (Agilent) [8, 68] .
Data analyses
Statistical analyses were performed using GRAPHPAD PRISM (GraphPad Software) by analyses of variance (ANOVA) for repeated measures, followed by the Bonferroni posthoc test, unless specified otherwise. P ≤ 0.05 values were considered significant.
